START Midwest‘s Nehal Lakhani, MD, PhD, was recently featured on OncLive after his poster examining SL-172154 (SIRPα-Fc-CD40L) was presented at the 2021 Society for Immunotherapy of Cancer (SITC)’s Annual Meeting. The investigative agent was found to be “well tolerated with no DLTs or evidence of anemia, thrombocytopenia, liver dysfunction, cytokine release syndrome, or pneumonitis,” Dr. Lakhani wrote in his poster. To learn more about his findings and presentation, visit OncLive.
START Midwest, located at CHCWM’s East facility, is part of START’s global network of Phase I clinical research sites. It is the largest Phase I oncology drug development program in Michigan and one of the largest in the Midwest. It offers cancer patients access to cutting-edge clinical trial drugs, including immunotherapy and targeted therapy options.
Becky Downing, Social Media & Marketing Specialist